Metabolomic and transcriptomic insights into gender-specific PFAS effects on liver diseaseShow others and affiliations
2025 (English)In: Journal of Hepatology, ISSN 0168-8278, E-ISSN 1600-0641, Vol. 82, no Suppl. 1, p. S112-S112, article id THU-491Article in journal, Meeting abstract (Other academic) Published
Abstract [en]
Background and aims: Per- and polyfluoroalkyl substances (PFAS) are emerging environmental pollutants linked to metabolic disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD). This study investigates the associations between PFAS exposure and MASLD progression, focusing on lipidomic, metabolomic, and transcriptomic biomarkers, functional pathways, and gender-specific responses.
Method: Metabolomic and lipidomic analyses were performed to examine changes in metabolite and lipid composition across steatosis grades (0–3) and between MASH-positive and MASH-negative samples. Transcriptomic data were analyzed using weighted gene co-expression network analysis (WGCNA), with KEGG pathway enrichment for functional insights. Mediation analysis explored whether specific metabolites mediated the association between PFAS exposure and steatosis.
Results: Lipidomic analysis revealed significant shifts in lipidcomposition with steatosis severity, including increased TG-SFA and TG-MUFA levels in MASH-positive samples and decreased phosphatidylinositol and phosphatidylcholine levels. Gender-specific transcriptomic analysis using WGCNA identified significant modules in both females and males. These modules were significantly negatively correlated with pathways, including arginine biosynthesis, amino acid metabolism, and other related processes in both genders. Metabolomics analysis supported these findings, identifying metabolites negatively correlated with MASLD progression enriched in similar pathways, implicating a disruption in amino acid metabolism with disease progression. Positively correlated transcriptomic modules in females were linked to cell cycle, steroid biosynthesis, and fatty acid metabolism. Furthermore, significant positive correlations were observed between PFAS compounds (e.g., PFUnDA, PFDoDA) and lipids such as phosphatidylinositol, while acylcarnitines showed negative correlations. Mediation analysis showed that specific metabolites partially mediated the relationship between PFAS exposure and steatosis. Phosphatidylinositol mediated the effect of PFHxA ( p = 0.002), TG-SFA mediated PFHpA’s effect ( p = 0.028), and lactosylceramide (Laccer) mediated PFHpA’s effect ( p = 0.004).
Conclusion: This study provides insights into the molecular mechanisms linking PFAS exposure to MASLD progression, high-lighting disrupted amino acid and lipid metabolism and gender-specific responses. Identifying specific metabolites as mediators highlights new targets for addressing PFAS-related liver diseases.
Place, publisher, year, edition, pages
Elsevier, 2025. Vol. 82, no Suppl. 1, p. S112-S112, article id THU-491
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-121697ISI: 001504520300102OAI: oai:DiVA.org:oru-121697DiVA, id: diva2:1972880
Conference
European Association for the Study of the Liver Congress (EASL 2025), Amsterdam, Netherlands, May 7-10, 2025
2025-06-192025-06-192025-06-24Bibliographically approved